samedan logo
 
 
spacer
home > ict > autumn 2017 > expert knowledge
PUBLICATIONS
International Clinical Trials

Expert Knowledge

After the US and Europe, Japan is the most important
market for biopharmaceutical R&D companies. The
Japanese pharmaceutical industry is worth $81 billion
and the major global companies have well-established
marketing and R&D operations in the region. Demands
for effective pharma products in Japan are growing,
but the current government emphasis on reducing
rising healthcare expenditure in the face of a rapidly
ageing population has made the business environment
challenging for the industry.

Japan has a mature, developed pharma market that is very
sensitive with respect to research quality, as the medical
community is exclusive, hierarchical and conservative.
Only 34% of clinical research is conducted by non-Japanese
businesses. During the late 1990s, several global CROs
expanded their operations, setting up offices in Japan to
coordinate global multicentre clinical trials as a part of their
drug development support to multinational companies.
In doing so, they have adapted to the different clinical
research environment in Japan, which is more resource-
focused and, therefore, more expensive when compared to
clinical trials in other regions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mary Pan is Vice President of General Management and Business Development at ICON, Asia Pacific, where she is responsible for growing and enhancing ICONís presence in the region. She has over 17 years of global pharma and clinical development expertise, with a strong track record in Asia through roles at Becton Dickinson, ClinTec International, Johnson & Johnson and Pfizer. Mary holds bachelor degrees in economics and psychology and a Master of Business Administration from Brown University, US, and also has a law degree from the University of Edinburgh, UK.
spacer
Mary Pan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sterling Pharma Solutions launches following management buyout


More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

Drug Discovery 2018

21-22 March 2018, Copthorne Tara Hotel, Scarsdale Place, Kensington, London

SMi Group is proud to announce the return of Drug Discovery in 2018. The successful conference will return for its 2nd year on the 21st and 22nd March.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement